[Toronto, April 9, 2025] – More than just another cancer research conference, AACR 2025 is where translational science and clinical innovation converge. This year’s theme, “Unifying Cancer Science and Medicine,” highlights the growing impact of research that bridges the bench to the clinic. Taking place in Chicago from April 25–30, it remains the premier stage for unveiling transformative cancer discoveries.

At AACR 2025, Geneseeq will showcase seventeen posters from both internal research and collaborative efforts, spanning minimal residual disease (MRD), cancer genomics, biomarker identification, and treatment response—reinforcing our commitment to innovation and excellence across multiple domains, from discovery to clinical impact.

Poster ID Topic Title

3263 / 28

Minimal residual disease (MRD)

Assessing molecular residual disease via early postoperative plasma circulating tumor DNA for recurrence risk evaluation in non-small cell lung cancer following radical resection

5897 / 22

Minimal residual disease (MRD)

Noninvasive tumor genetic profiling and disease surveillance in mantle cell lymphoma via plasma circulating tumor DNA

4561 / 14

Panel development & Minimal residual disease (MRD)

ShieldingUltra: A novel approach for enhanced minimal residual disease detection through the integration of mutation, copy number variation, and fragmentomics

5055 / 26

Panel development

Efficient detection of chromosomal instability in diverse cancers using a targeted sequencing approach

2403 / 21

Panel development

Efficient detection of whole genome duplication: a targeted sequencing approach

5053 / 24

Panel development

Targeted sequencing panel for comprehensive MTAP deletion detection in diverse cancer types

5369 / 23

Cancer genomics

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analyses

1956 / 24

Cancer genomics

Comparison of somatic variations between circulating tumor DNA and paired tissue in 1,111 pan-cancer patients

3398 / 18

Cancer genomics

Gene-level and global genomic insights into colorectal cancer ovarian metastasis: Molecular mechanisms and determinants

5007 / 11

Biomarker identification

Integrated histology-genomic multimodel deep learning to predict prognosis in non-small-cell lung cancer

2183 / 7

Biomarker identification

DNAH mutations as a potential biomarker for immune checkpoint inhibitor response and survival

5368 / 22

Biomarker identification

The differences in molecular profiles and survival outcomes between early and late-onset glioblastoma

2052 / 21

Biomarker identification

Genomic and transcriptomic correlates of response to neoadjuvant chemotherapy and survival outcomes in breast cancer

5367 / 21

Treatment response

Distinct molecular characteristics and treatment implications of TP53 gain-of-function mutations in non-small cell lung cancer

3397 / 17

Treatment response

Survival stratification for TP53-mutated endometrial cancers under platinum-based chemotherapy

722 / 7

Treatment response

Characterization and estimation of treatment response of immunotherapy-based total neoadjuvant therapy (iTNT) for microsatellite stable (MSS) locally advanced rectal cancer

5357 / 11

Treatment response

Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer
AACR Biomarker Cancer Research MRD NGS Precision Oncology